Transfusion-related acute lung injury

EQS-News: Lindis Blood Care Announces Last Patient Out in Multicenter Clinical Certification Study REMOVE with CATUVAB® to Eliminate Tumor Cells from Surgical Blood

Retrieved on: 
Wednesday, December 20, 2023
FDA, Ovary, Blood, Transfusion-related acute lung injury, Certification, Risk, Lung, Patient, Hospital, Regulation, Cell, Cancer, Carcinoma, IBS, Immunosuppression, Infection, Metastasis, Lymphocyte, Medical imaging, Medical device, Epithelial cell adhesion molecule

Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB® for the removal of tumor cells from surgical shed blood, today announced that the last patient in its certification study REMOVE has successfully completed the trial.

Key Points: 
  • Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB® for the removal of tumor cells from surgical shed blood, today announced that the last patient in its certification study REMOVE has successfully completed the trial.
  • REMOVE, a confirmation open-label multicenter clinical study, enrolled 130 patients being one of the largest studies assessing a medical device for the removal of tumor cells in an intraoperative blood salvage (IBS) procedure.
  • CATUVAB® is designed to reliably remove cells from EpCAM (epithelial cell adhesion molecule)-positive tumors from patient blood during cancer surgeries.
  • This procedure aims to be an easy-to-implement method that combines trifunctional antibody that aggregates the tumor cells and lymphocytes with current filter technologies and intraoperative blood salvage devices available at nearly all hospitals.

Abstrax and AVD Advance Inhalation Safety for the Cannabis Industry

Retrieved on: 
Wednesday, November 29, 2023
Acetate, Genotoxicity, Global Food Safety Initiative, Safety, Quality, Regulation, Aerosol, AVD, McKinney, Texas, Gold, Risk assessment, Certification, ISO, Culture, Science, GFSI, CMR, Transfusion-related acute lung injury, EZ, ISO 9001:2015, Medical device, Mutagen, Cytotoxicity

TUSTIN, Calif., Nov. 28, 2023 /PRNewswire-PRWeb/ -- Abstrax, the leader in botanical flavor technology, is thrilled to announce its partnership with Advanced Vapor Devices LLC (AVD), a leader in cannabis vaporizer technology, and McKinney Regulatory Science Advisors LLC to create and execute the cannabis industry's most comprehensive inhalation risk evaluation program.

Key Points: 
  • To accomplish this, the Abstrax team designed a special algorithm , based on robust consumer use data from multiple manufacturers of inhalable cannabis products.
  • The AVD collaboration has helped bolster RA-TEP's algorithm to offer a more realistic view of consumers' use and exposure.
  • "By elevating the standards of inhalation safety and compliance, we're not just safeguarding the consumer, but also pioneering a path of scientific rigor and integrity for the cannabis industry.
  • "We recognize the cannabis industry is facing a pivotal moment where the convergence of innovation and safety will mold and shape its future," said Casey Creaney, VP of Product Integration at AVD.

Breathing new life into patient care: Innovative partnership aims to transform interstitial lung disease support

Retrieved on: 
Wednesday, October 25, 2023
Patient, Research, COPD, McMaster Faculty of Engineering, Faculty, Engineering, McMaster University, Therapy, Periodic breathing, Firestone Institute for Respiratory Health, Transfusion-related acute lung injury, Life, Hope, McMaster, Student, Fibrosis, St. Joe, Health, Quality of life, St. Joseph's Healthcare Hamilton, Caregiver, Internet, Disease, Boehringer Ingelheim, Emotion, Confusion, Market access, Asthma, Partnership, ILD, Depression, Anxiety, Diagnosis, Empathy, Associate, Uncertainty, Mental health, Medical device, Nursing, BURLINGTON, Medicine

"Having the opportunity to work with ILD patients has been a deeply humbling and rewarding experience.

Key Points: 
  • "Having the opportunity to work with ILD patients has been a deeply humbling and rewarding experience.
  • "ILD is a complex, life-altering disease where Canadians often do not get the information they need at diagnosis.
  • Boehringer Ingelheim Canada, St. Joseph's Healthcare Hamilton, and McMaster University are committed to transforming the ILD patient experience.
  • Research is wide-ranging, from basic studies of animal models of lung disease (asthma, COPD, fibrosis) to clinical trials, epidemiological studies, and evaluative research.

GE HealthCare Signs $44 Million Contract with BARDA to Develop Artificial Intelligence-Augmented Ultrasound Technology to Aid Clinicians in Diagnosing and Treating Traumatic Injury and Enhance National Preparedness for Mass Casualty Incidents

Retrieved on: 
Thursday, October 12, 2023
Radiology, White House, Federal Government, Artificial Intelligence, Medical Devices, Infectious Diseases, Hospitals, Homeland Security, Professional Services, Data Management, Technology, Public Policy, Government, General Health, Biotechnology, Data Analytics, Health, Law Enforcement, Emergency Services, Public Safety, Apps, Applications, Health Technology, Triage, Infection, Hospital, ASPR, Acquisition, Abdomen, Death, Development, Office of Inspector General, U.S. Department of Health and Human Services, Standard of care, Human services, AI, Administration for Strategic Preparedness and Response, Injury, Administration, Transfusion-related acute lung injury, Survival, Trauma, Artificial intelligence, Biomedical Advanced Research and Development Authority, GE, Head, GE HealthCare, BARDA, HHS, Patient, Medical imaging, Ultrasound

Trauma is a leading cause of death in the United States1 posing an enormous burden to healthcare systems and society.

Key Points: 
  • Trauma is a leading cause of death in the United States1 posing an enormous burden to healthcare systems and society.
  • Injury detection and triage of trauma patients play key roles in successful patient care and resource management, both in everyday situations and in mass casualty events.
  • Technologies that expedite care, including detection, evaluation, and decision-assist capabilities, potentially increase patients’ chances of survival.
  • “Point-of-care ultrasound is an essential tool in emergency situations to help clinicians quickly get the answers they need when treating patients,” said Roland Rott, President and CEO, Ultrasound, GE HealthCare.

Global Acute Respiratory Distress Syndrome Market Report 2023-2028: Industry Trends, Growth, Impact of Inflation, Opportunities, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 7, 2023
Pharmaceutical, Health, Medical Devices, Research and development, Failure, Bed, Hospital, COVID-19, Ageing, Risk, Lung, Government, Incidence, Chronic Respiratory Disease, Patient, Transfusion-related acute lung injury, Developed country, Viral, Acute respiratory distress syndrome, ICU, R, Air pollution, Diagnosis, White lung, Dietary supplement, Pharmaceutical industry, Medical device, Nursing, Growth

The "Acute Respiratory Distress Syndrome Market, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acute Respiratory Distress Syndrome Market, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The other factors forecasted to propel the development of the worldwide acute respiratory distress syndrome (ARDS) market include the rising rate of air pollution and lifestyle-related diseases and Increasing accident rates and trauma-causing ARDS market.
  • However, the high cost of devices, lack of awareness about diseases, failure of trials for ARDS, and stringent regulation for approvals are the main factors restraining the global acute respiratory distress syndrome market.
  • In addition, nebulization devices dominate the acute respiratory distress syndrome market due to their low cost and wide availability.

Anti-Cancer Potential of Rencofilstat Expanded with Results from Preclinical Multiple Myeloma Studies

Retrieved on: 
Wednesday, January 18, 2023
Degenerative disease, Gene expression, Cell, Prostate cancer, Cancer, Multiple myeloma, Fatty liver disease, Doctor of Pharmacy, Conditional sentence, Bortezomib, HEPA, Immortalised cell line, Research, Fibrosis, Liver cancer, Artificial intelligence, Transfusion-related acute lung injury, Doctor of Philosophy, NASH, Pharmaceutical industry, Vaccine

EDISON, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced positive results of preclinical studies examining rencofilstat as a potential therapeutic for multiple myeloma (“MM”).

Key Points: 
  • Rencofilstat exerted anti-cancer activity across a large panel of MM cell lines, and most potently, in combination with bortezomib, a proteosome inhibitor and first-line treatment for MM.
  • These results strengthen Hepion’s oncology initiatives and further support rencofilstat’s poly-indication potential.
  • The combination of rencofilstat and bortezomib produced 100% cytotoxicity in cell culture experiments across all 16 MM cell lines, including three lines that are characterized as bortezomib-resistant.
  • The cytotoxic activity of rencofilstat plus bortezomib was synergistic in every cell line, showing greater cytotoxicity in combination than the sum of the two drugs individually.

JUVENESCENCE Appoints Dr Richard Marshall CBE as CEO

Retrieved on: 
Monday, January 16, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Ecosystem, Ageing, COVID-19, CBE, Senior, AstraZeneca, Growth, DPU, Fibrosis, Transfusion-related acute lung injury, GSK, D, Immunology, Pharmaceutical industry

Juvenescence has named Dr Richard Marshall CBE as its new CEO, effective 16 January 2023.

Key Points: 
  • Juvenescence has named Dr Richard Marshall CBE as its new CEO, effective 16 January 2023.
  • Dr Marshall succeeds co-founder Dr Gregory Bailey, who will remain on the company’s board as Executive Chairman.
  • Dr Marshall was awarded a CBE in the 2021 Queen’s Honours List for his contribution to UK science and COVID-19.
  • “I am delighted that Dr Richard Marshall CBE, the former Senior Vice-President, Global Head of Development, Respiratory & Immunology at AstraZeneca, has agreed to lead Juvenescence as CEO.

Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan

Retrieved on: 
Thursday, February 2, 2023
Pulmonary fibrosis, Teaching hospital, COVID-19, End organ damage, Chemokine, University Hospital of Basel, Pathology, RNA-Seq, PD, Lung, Patient, Idiopathic pulmonary fibrosis, FVC, Transfusion-related acute lung injury, Probability, IPF, KNRS, Pharmaceutical industry, Pirfenidone, Muthiri kinaru

Kinarus Therapeutics AG (SIX:KNRS) “Kinarus”, a Swiss clinical-stage biopharmaceutical company announced today preclinical data supporting the potential effectiveness of its lead clinical candidate, KIN001, as an oral treatment for idiopathic pulmonary fibrosis (IPF).

Key Points: 
  • Kinarus Therapeutics AG (SIX:KNRS) “Kinarus”, a Swiss clinical-stage biopharmaceutical company announced today preclinical data supporting the potential effectiveness of its lead clinical candidate, KIN001, as an oral treatment for idiopathic pulmonary fibrosis (IPF).
  • In a mouse model of lung injury, KIN001 significantly reduced lung weights and tissue fibrosis score vs. controls.
  • The combination of KIN001 with pirfenidone demonstrated greater reduction in lung fibrosis, indicating the potential for additional benefit of KIN001 in combination with the current standard of care.
  • KIN001 significantly reduced the upregulation of multiple key inflammatory cytokines and chemokines implicated in the pathology of lung fibrosis.

Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan

Retrieved on: 
Tuesday, January 17, 2023
Pulmonary fibrosis, Teaching hospital, COVID-19, End organ damage, Chemokine, University Hospital of Basel, Pathology, RNA-Seq, PD, Lung, Patient, Idiopathic pulmonary fibrosis, FVC, Transfusion-related acute lung injury, Probability, IPF, KNRS, Pharmaceutical industry, Pirfenidone, Muthiri kinaru

Kinarus Therapeutics AG (SIX:KNRS) “Kinarus”, a Swiss clinical-stage biopharmaceutical company announced today preclinical data supporting the potential effectiveness of its lead clinical candidate, KIN001, as an oral treatment for idiopathic pulmonary fibrosis (IPF).

Key Points: 
  • Kinarus Therapeutics AG (SIX:KNRS) “Kinarus”, a Swiss clinical-stage biopharmaceutical company announced today preclinical data supporting the potential effectiveness of its lead clinical candidate, KIN001, as an oral treatment for idiopathic pulmonary fibrosis (IPF).
  • In a mouse model of lung injury, KIN001 significantly reduced lung weights and tissue fibrosis score vs. controls.
  • The combination of KIN001 with pirfenidone demonstrated greater reduction in lung fibrosis, indicating the potential for additional benefit of KIN001 in combination with the current standard of care.
  • KIN001 significantly reduced the upregulation of multiple key inflammatory cytokines and chemokines implicated in the pathology of lung fibrosis.

Vizgen Launches MERSCOPE™ Formalin-Fixed Paraffin-Embedded (FFPE) Solution Kit

Retrieved on: 
Thursday, December 8, 2022
Research, Infectious Diseases, Neurology, Genetics, Biotechnology, Health, Other Science, Science, Oncology, Data, Social media, Infection, Translational Genomics Research Institute, Lung, Drug discovery, Patient, Cancer, Research, Disease, Catalog, Genomics, Transfusion-related acute lung injury, Multimedia, Pulmonary fibrosis, Neuroscience, Health, Organic acid, RNA, Developmental biology, Associate, Microscope, Medical imaging

Earlier this year, Vizgen released its FFPE Human Immuno-oncology dataset , the largest public data set for single-cell spatial genomics released to date, which was generated by an early version of the MERSCOPE FFPE solution.

Key Points: 
  • Earlier this year, Vizgen released its FFPE Human Immuno-oncology dataset , the largest public data set for single-cell spatial genomics released to date, which was generated by an early version of the MERSCOPE FFPE solution.
  • The MERSCOPE FFPE Solution includes new sample preparation kits, user-friendly workflow, and updated innovative segmentation software to enable researchers to effectively process, image, and analyze FFPE samples.
  • The MERSCOPE FFPE Solution is immediately compatible with existing systems and with Vizgens newly released protein co-detection solution.
  • Together with its impressive reproducibility between matched fresh frozen and FFPE tissue samples, the MERSCOPE FFPE solution delivers biologically impactful data.